Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial

Background C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease. We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. Study Design Open-label, multicenter, randomized, parallel-group, phase 3 study. Setting & Participants Dialysis patients (age ≥ 18 years). Intervention Patients (n = 181) were randomly assigned (3:1) to receive intravenous C.E.R.A. once every 2 weeks or epoetin 3 times weekly. Outcomes & Measurements The primary end point was Hb level response rate (increase in Hb level ≥ 1 g/dL [10 g/L] versus baseline and Hb level ≥ 11 g/dL [110 g/L] without blood transfusion during the 24-week correction period) in the intent-to-treat population. Results Hb response rates (intent-to-treat population) were 93.3% with C.E.R.A. and 91.3% with epoetin. Similar results were found in the per-protocol population. Peak mean Hb levels were 12.28 ± 1.13 (SD) g/dL (122.8 ± 11.3 g/L) with C.E.R.A. and 12.19 ± 1.24 g/dL (121.9 ± 12.4 g/L) with epoetin. Mean change in Hb levels from baseline to the end of the correction period were 2.70 ± 1.45 g/dL (27 ± 14.5 g/L) with C.E.R.A. and 2.56 ± 1.31 g/dL (25.6 ± 13.1 g/L) with epoetin. Both treatments were generally well tolerated. Limitations Open-label study design, 3:1 randomization, limited peritoneal dialysis population, descriptive statistics, and lack of formal prespecified comparison to epoetin. Conclusions Intravenous C.E.R.A. once every 2 weeks may be as safe and effective as 3-times-weekly epoetin for correcting anemia in dialysis patients. These results show the utility of intravenous C.E.R.A. administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease. We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients. Open-label, multicenter, randomized, parallel-group, phase 3 study. Dialysis patients (age ≥ 18 years). Patients (n = 181) were randomly assigned (3:1) to receive intravenous C.E.R.A. once every 2 weeks or epoetin 3 times weekly. The primary end point was Hb level response rate (increase in Hb level ≥ 1 g/dL [10 g/L] versus baseline and Hb level ≥ 11 g/dL [110 g/L] without blood transfusion during the 24-week correction period) in the intent-to-treat population. Hb response rates (intent-to-treat population) were 93.3% with C.E.R.A. and 91.3% with epoetin. Similar results were found in the per-protocol population. Peak mean Hb levels were 12.28 ± 1.13 (SD) g/dL (122.8 ± 11.3 g/L) with C.E.R.A. and 12.19 ± 1.24 g/dL (121.9 ± 12.4 g/L) with epoetin. Mean change in Hb levels from baseline to the end of the correction period were 2.70 ± 1.45 g/dL (27 ± 14.5 g/L) with C.E.R.A. and 2.56 ± 1.31 g/dL (25.6 ± 13.1 g/L) with epoetin. Both treatments were generally well tolerated. Open-label study design, 3:1 randomization, limited peritoneal dialysis population, descriptive statistics, and lack of formal prespecified comparison to epoetin. Intravenous C.E.R.A. once every 2 weeks may be as safe and effective as 3-times-weekly epoetin for correcting anemia in dialysis patients. These results show the utility of intravenous C.E.R.A. administered once every 2 weeks in erythropoiesis-stimulating agent–naive dialysis patients.